Current treatment status-Not currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Searching for patients with previously treated colorectal cancer to test this new immunotherapy option

Posted by on Jun 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1b trial is examining the effectiveness and safety of cibisatamab in combination with atezolizumab (Tecentriq) after treatment with obinutuzumab (Gazyva) in patients with previously treated metastatic colorectal carcinoma (mCRC).  The main outcomes to be measured will be side effects and...

Read More

Evaluating brentuximab vedotin plus high-dose bendamustine for relapsed or unresponsive Hodgkin lymphoma

Posted by on May 31, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...

Read More

Looking for participants with advanced colorectal cancer to test a new targeted treatment with DS-8201a

Posted by on May 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects.  The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...

Read More

Evaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma

Posted by on Apr 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...

Read More

Searching for patients to try a new combination of treatments for relapsed or unresponsive Hodgkin lymphoma.

Posted by on Apr 22, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...

Read More

Optimal treatment for relapsed and unresponsive nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Apr 18, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate treatments and outcomes for patients with relapsed or unresponsive nodular lymphocyte-predominant Hodgkin lymphoma. This study concluded that these patients have a good overall prognosis and treatments should be chosen individually. Some background Radiotherapy (RT), chemotherapy (CT) and rituximab...

Read More

Searching for patients to try a combination treatment for multiple myeloma.

Posted by on Apr 17, 2019 in Multiple Myeloma | 0 comments

In a nutshell The study will investigate the effects of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (Decadron) in multiple myeloma (MM). The main outcome that will be measured will be the percentage of patients who have no signs or symptoms of MM after treatment (completed response). This study is recruiting in Georgia, Unites...

Read More

New treatment improves tumor response in patients with HER2 positive metastatic colorectal cancer

Posted by on Apr 8, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Some background...

Read More

Comparing conditioning regimens before stem cell transplantation for patients with Hodgkin lymphoma

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens before autologous stem cell transplantation (ASCT) for patients with Hodgkin lymphoma (HL). This study concluded that BEAM conditioning before ASCT significantly improved the outcomes of these patients. Some background About 20 – 30% of patients...

Read More

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...

Read More